Abstract: Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectorations, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils.

Abstract: A computer-implemented method and a system for providing anatomical landmarks of a subject's body part using a set of measures previously acquired by an ultrasound device including at least one fiducial marker and an imaging sensor. Also, a non-transitory computer readable medium including instructions which, when the program is executed by a computer, cause the computer to carry out the method.

Abstract: A method for measuring respiratory parameters of a subject using a range imaging sensor, wherein the method includes: receiving from the range imaging sensor at least one raw image of at least one portion of the torso of the subject, wherein each point of the raw image represents the distance between the range imaging sensor and the subject; generating a surface image of at least one portion of a surface of the torso of the subject by surface interpolation of the raw image; estimating a respiratory signal as a function of time calculated as the spatial average, in a given region of interest (ROI) defined on the torso of the subject, of the differences between the depth values of the surface image at a given time and the depth values of a reference surface image; and estimating a lung volume.

Abstract: Activating transcription factor 6 (ATF6) is involved in cystic fibrosis transmembrane conductance regulator (CFTR) repression and understanding this inhibitory mechanism is of great interest to develop a therapeutic approach based on UPR regulation. Using site-1 protease (S1P) inhibitor (e.g. PF-429242) the inventors showed that both membrane localization and function of F508del-CFTR are partially restored. Accordingly, the present invention relates to a method of treating a disease associated with reduced CFTR function in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a S1P inhibitor.

Abstract: Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectoration, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils.

Abstract: Some embodiments are directed to a process for the diagnosis of systemic lupus erythematosus (SLE) and/or of chronic lymphoid leukaemia (CLL) of a subject who may be suffering therefrom, comprising the in vitro detection of the expression of the fraction of the STIM1 protein located at the cell plasma membrane in a biological sample from human and mice. Some other embodiments are directed to a process for predicting the progression and/or monitoring the progression of CLL and/or of SLE, comprising the in vitro detection of the expression of the fraction of the STIM1 protein located at the cell plasma membrane.

Abstract: Disclosed are novel branched amphiphilic lipids, in particular novel branched amphiphilic lipids of general formula (II). Also disclosed is a method of synthesis for the compounds of formula (II), from unsaturated amphiphilic compounds of general formula (I). Further disclosed is the use of the compounds of general formula (II) and of the lipoplexes obtained by formulation of the compounds of general formula (II) for applications, particularly transfection, in which improved fusion properties are desired.

Abstract: The invention relates to an active implantable pacemaker. The device analyzes a ventricular electrogram signal (EGM) and is able to recognize, in a search window, an EA4 component of endocardial acceleration (EA) associated with atrial activity. In the presence of atrioventricular conduction, the search window is determined based on the temporal position of the EA1 and/or EA2 components of the EA signal. In the absence of atrioventricular conduction, a delay is counted from a paced ventricular event and applied to mask the EA1 and/or EA2 components in the EA signal, and the window for research of the EA4 component follows the masking delay. In the presence of a confirmed EA4 component, an atrioventricular delay is applied, counted from the EA4 component, and in the opposite case a predetermined escape interval is applied, counted from the last stimulated ventricular event.